Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Regenxbio, Inc. breached fiduciary duties by providing false or misleading information about the efficacy and safety of RGX-111, a gene therapy for Hurler Syndrome. The firm is seeking shareholders who purchased stock prior to February 9, 2022.